Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 16/20 | 0.44 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | AKT2 | P31751 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19304118 | 0.82 | TRPA1 (0.55) | ROCK2ROCK1TRPA1AKT1AKT2 | |
| SCHEMBL18375564 | 0.81 | AKT1 (0.42) | ROCK2ROCK1TRPA1AKT1AKT2 | |
| SCHEMBL17194915 | 0.80 | AKT1 (0.43) | ROCK2ROCK1RPS6KA2AKT1AKT2 | |
| SCHEMBL20150115 | 0.78 | CYP17A1 (0.35) | TRPA1 | |
| SCHEMBL20995329 | 0.77 | AKT2 (0.47) | ROCK2ROCK1TRPA1AKT1AKT2 | |
| SCHEMBL617346 | 0.77 | PDE4B (0.43) | — | |
| SCHEMBL20150090 | 0.75 | METAP2 (0.55) | — | |
| SCHEMBL21784426 | 0.74 | TTK (0.41) | — | |
| SCHEMBL20150080 | 0.73 | IDO1 (0.44) | TRPA1 | |
| SCHEMBL20150106 | 0.73 | TP53 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ROCK2 246/4885ROCK1 411/4885RPS6KA2 491/4885 |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ROCK2 246/4885ROCK1 411/4885RPS6KA2 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.